Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 16 to 19 of 19 results for pertuzumab

  1. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.

  2. Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

    In development [GID-TA10592] Expected publication date: TBC

  3. NICE provides access to new treatment option for advanced breast cancer

    NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).

  4. Around 400 people with advanced breast cancer are set to benefit from a new treatment

    Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.